Galmed Pharmaceuticals Ltd. – NASDAQ:GLMD
Founder-led company
Galmed Pharmaceuticals Ltd. stock price today
$1.4
-1.72
-55.13%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 9 hours
Galmed Pharmaceuticals Ltd. stock price monthly change
+937.58%
month
Galmed Pharmaceuticals Ltd. stock price quarterly change
+937.58%
quarter
Galmed Pharmaceuticals Ltd. stock price yearly change
+609.09%
year
Galmed Pharmaceuticals Ltd. key metrics
Market Cap | 5.18M |
Enterprise value | 3.96M |
P/E | -0.46 |
EV/Sales | N/A |
EV/EBITDA | -0.17 |
Price/Sales | N/A |
Price/Book | 0.50 |
PEG ratio | -0.20 |
EPS | -1.81 |
Revenue | N/A |
EBITDA | -6.85M |
Income | -6.35M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeGalmed Pharmaceuticals Ltd. stock price history
Galmed Pharmaceuticals Ltd. stock forecast
Galmed Pharmaceuticals Ltd. financial statements
| Jun 2023 | 0 | -1.59M | |
|---|---|---|---|
| Sep 2023 | 0 | -1.47M | |
| Dec 2023 | 0 | -2.01M | |
| Mar 2024 | 0 | -1.27M |
| 2027 | 0 | -2.79M |
|---|
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 13277000 | 2.72M | 20.51% |
|---|---|---|---|
| Sep 2023 | 17638000 | 2.09M | 11.86% |
| Dec 2023 | 16629000 | 2.75M | 16.54% |
| Mar 2024 | 14521000 | 1.76M | 12.15% |
| Jun 2023 | -1.36M | 705K | 0 |
|---|---|---|---|
| Sep 2023 | -2.17M | -3.53M | 6.18M |
| Dec 2023 | -898K | 2.27M | 0 |
| Mar 2024 | -1.83M | 432K | 0 |
Galmed Pharmaceuticals Ltd. alternative data
| Aug 2023 | 4 |
|---|---|
| Sep 2023 | 4 |
| Oct 2023 | 4 |
| Nov 2023 | 4 |
| Dec 2023 | 4 |
| Jan 2024 | 4 |
| Feb 2024 | 4 |
| Mar 2024 | 4 |
| Apr 2024 | 4 |
| May 2024 | 3 |
| Jun 2024 | 3 |
| Jul 2024 | 3 |
Galmed Pharmaceuticals Ltd. other data
11.42%
-4.02%
of GLMD is owned by hedge funds
2.80M
-1.06M
shares is hold by hedge funds
| Quarter | Transcript |
|---|---|
| Q4 2021 2 May 2022 | Q4 2021 Earnings Call Transcript |
| Q3 2021 8 Nov 2021 | Q3 2021 Earnings Call Transcript |
| Q2 2021 9 Aug 2021 | Q2 2021 Earnings Call Transcript |
| Q1 2021 13 May 2021 | Q1 2021 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Allen Baharaff (1965) Co-Founder, Pres, Chief Executive Officer & Chairman | $766,580 |
Dr. Liat Hayardeny (1967) Chief Scientific Officer | $215,450 |
Dr. Tali Gorfine (1970) Medical Consultant | $202,760 |
Mr. Guy Nehemya (1985) Chief Operating Officer | $167,540 |
Mr. Yohai Stenzler (1983) Chief Financial Officer | $167,260 |
-
What's the price of Galmed Pharmaceuticals Ltd. stock today?
One share of Galmed Pharmaceuticals Ltd. stock can currently be purchased for approximately $1.4.
-
When is Galmed Pharmaceuticals Ltd.'s next earnings date?
Unfortunately, Galmed Pharmaceuticals Ltd.'s (GLMD) next earnings date is currently unknown.
-
Does Galmed Pharmaceuticals Ltd. pay dividends?
No, Galmed Pharmaceuticals Ltd. does not pay dividends.
-
How much money does Galmed Pharmaceuticals Ltd. make?
Galmed Pharmaceuticals Ltd. has a market capitalization of 5.18M.
-
What is Galmed Pharmaceuticals Ltd.'s stock symbol?
Galmed Pharmaceuticals Ltd. is traded on the NASDAQ under the ticker symbol "GLMD".
-
What is Galmed Pharmaceuticals Ltd.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Galmed Pharmaceuticals Ltd.?
Shares of Galmed Pharmaceuticals Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Galmed Pharmaceuticals Ltd.'s key executives?
Galmed Pharmaceuticals Ltd.'s management team includes the following people:
- Mr. Allen Baharaff Co-Founder, Pres, Chief Executive Officer & Chairman(age: 60, pay: $766,580)
- Dr. Liat Hayardeny Chief Scientific Officer(age: 58, pay: $215,450)
- Dr. Tali Gorfine Medical Consultant(age: 55, pay: $202,760)
- Mr. Guy Nehemya Chief Operating Officer(age: 40, pay: $167,540)
- Mr. Yohai Stenzler Chief Financial Officer(age: 42, pay: $167,260)
-
Is Galmed Pharmaceuticals Ltd. founder-led company?
Yes, Galmed Pharmaceuticals Ltd. is a company led by its founder Mr. Allen Baharaff.
-
How many employees does Galmed Pharmaceuticals Ltd. have?
As Jul 2024, Galmed Pharmaceuticals Ltd. employs 3 workers, which is 25% less then previous quarter.
-
When Galmed Pharmaceuticals Ltd. went public?
Galmed Pharmaceuticals Ltd. is publicly traded company for more then 11 years since IPO on 13 Mar 2014.
-
What is Galmed Pharmaceuticals Ltd.'s official website?
The official website for Galmed Pharmaceuticals Ltd. is galmedpharma.com.
-
How can i contact Galmed Pharmaceuticals Ltd.?
Galmed Pharmaceuticals Ltd. can be reached via phone at +972 3 693 8448.
Galmed Pharmaceuticals Ltd. company profile:
Galmed Pharmaceuticals Ltd.
galmedpharma.comExchange:
NASDAQ
Full time employees:
3
Industry:
Biotechnology
Sector:
Healthcare
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.
16 Tiomkin Street
Tel Aviv, 6578317
Tel Aviv, 6578317
CIK: 0001595353
ISIN: IL0011313900
CUSIP: M47238106
